The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 1,660,122 | 3,106,416 |
| Dividends and interest on marketable securities held in trust account | 1,873,780 | 3,674,951 |
| Prepaid expenses and other current assets | -87,390 | -91,237 |
| Due to sponsor | -30,000 | -44,762 |
| Accounts payable and accrued expenses | 8,163 | 29,617 |
| Net cash used in operating activities | -88,105 | -402,919 |
| Proceeds from note payable - related party | 100,000 | - |
| Net cash provided by financing activities | 100,000 | - |
| Net change in cash | 11,895 | -402,919 |
| Cash and cash equivalents at beginning of period | 438,174 | - |
| Cash and cash equivalents at end of period | 47,150 | - |
Translational Development Acquisition Corp. (TDACU)
Translational Development Acquisition Corp. (TDACU)